Enomoto, Noriyuki
Suzuki, Seiichiro
Hozumi, Hironao
Karayama, Masato
Suzuki, Yuzo
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Odagiri, Keiichi
Ishikawa, Takamichi
Kataoka, Kensuke
Kondoh, Yasuhiro
Maekawa, Masato
Inui, Naoki
Watanabe, Hiroshi
Suda, Takafumi
Article History
Received: 9 May 2021
Accepted: 12 July 2021
First Online: 29 July 2021
Competing interests
: This research was not funded. The authors declare the following competing interests outside the submitted work: Dr. Kondoh reports personal fees from Asahi Kasei Pharma Corp., personal fees from Shionogi & Co. Ltd., personal fees from Boehringer Ingelheim Co., Ltd., personal fees from Janssen Pharmaceutical K.K., personal fees from Healios K.K., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from AstraZaneca K.K, personal fees from Eisai inc., personal fees from KYORIN Pharmaceutical Co. Ltd., personal fees from Mitsubishi Tanabe Pharma, personal fees from Novartis Pharma K.K., outside the submitted work. Dr. Watanabe reports personal fees from Janssen Pharmaceuticals K.K., personal fees from Idorsia, personal fees from Nippon-Shinyaku, personal fees from Daiichi-Sankyo, personal fees from Kowa, personal fees from Nippon Shinyaku, outside the submitted work. Dr. Suda reports other from Boehlinger Ingelhem, other from Shionogi, outside the submitted work. Other authors declare no competing interests.